Intuitive Surgical earnings showed higher revenue and adjusted profit for the third quarter of 2026, but a litigation settlement charge reduced reported net income. The robotic-surgery company released its results on October 20 for the quarter ended September 30. Its shares declined on October 21 as attention turned to the company’s full-year procedure-growth outlook.
Key Takeaways
- Revenue rose 22% to $3.05 billion, while adjusted diluted earnings increased to $3.00 per share.
- A $450 million pre-tax litigation charge helped push GAAP net income down to $523 million.
- Management expects full-year da Vinci procedure growth near the midpoint of its 14%–15% range.
Table of Contents
- Intuitive Surgical earnings separate operating growth from legal costs
- Procedure volumes and system placements support sales
- Full-year outlook centers on procedure growth and tariffs
- Conclusion
Intuitive Surgical earnings separate operating growth from legal costs
The company’s third-quarter earnings release showed non-GAAP net income of $1.05 billion, up from $867 million a year earlier. Adjusted diluted earnings per share rose to $3.00 from $2.40.
GAAP results moved in the opposite direction. Net income fell to $523 million, or $1.49 per diluted share, from $704 million, or $1.95 per share. The quarter included a $450 million pre-tax charge tied to a proposed settlement of previously disclosed antitrust class-action litigation.
Intuitive reached a written settlement agreement in October without admitting liability or wrongdoing. The agreement calls for a one-time payment and mutually agreed injunctive relief, but remains subject to preliminary and final court approval. The charge reduced quarterly earnings by $347 million after tax, or $0.99 per diluted share.
Both GAAP and adjusted net income also included a $22 million after-tax benefit, equivalent to $0.06 per diluted share, from refunds of tariffs paid in prior periods. That benefit is relevant when comparing the quarter’s earnings with the prior year.
| Item | Details |
|---|---|
| Da Vinci installed base | 12,094 systems at September 30, 2026; up 12% year over year. |
| Ion installed base | 1,152 systems at September 30, 2026; up 21% year over year. |
| Quarterly share repurchases | 7.8 million shares repurchased for $2.94 billion. |
| Cash, cash equivalents and investments | $6.80 billion at quarter-end, down $1.83 billion during the quarter. |
Procedure volumes and system placements support sales
Worldwide procedures using da Vinci and Ion systems increased approximately 15% from a year earlier. Da Vinci procedures grew approximately 14%, while Ion procedures increased approximately 31%.
Procedure activity matters beyond equipment sales because it supports demand for instruments and accessories. Revenue from those products increased 18% to $1.80 billion, with Intuitive identifying procedure growth as the primary driver.
Systems revenue rose to $769 million from $590 million. The company placed 546 da Vinci systems during the quarter, compared with 427 a year earlier; the latest-generation da Vinci 5 accounted for 315 placements, up from 240.
Higher procedure volumes, operating lease revenue and the expanding installed base together drove the increase in total revenue, the company said.
Full-year outlook centers on procedure growth and tariffs
Management expects worldwide da Vinci procedure growth of approximately 14%–15% for 2026 and anticipates finishing closer to the midpoint of that range. This is guidance for the full year, distinct from the approximately 14% growth recorded in the third quarter.
The company forecasts a non-GAAP gross profit margin of 68.7%–69.3% and non-GAAP operating expense growth of 11%–13% for 2026.
The margin outlook includes an estimated tariff impact equal to 0.9% of revenue, excluding recognized tariff refunds. It assumes tariffs in effect at the release date remain in place through year-end. Intuitive cautioned that additional tariffs could materially affect its financial results.
Conclusion
Intuitive’s quarter combined expanding surgical activity and higher adjusted earnings with a substantial legal charge. The remaining fourth-quarter performance will determine where annual procedure growth lands within management’s forecast, while the proposed antitrust settlement still requires court approval.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
